Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 12, Issue 6, 2013, Pages 575-583

  Stanojevic, Sanja ^a   Ratjen, Felix ^a   Stephens, Derek ^b   Lu, Annie ^a   Yau, Yvonne ^a   Tullis, Elizabeth ^c,d   Waters, Valerie ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Epidemiology; Latent class models; Risk factors; Stenotrophomonas maltophilia

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; TIMENTIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; BACTERIUM CULTURE; BURKHOLDERIA CEPACIA COMPLEX; CHILD; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENOTYPE; HAEMOPHILUS INFECTION; HUMAN; INCIDENCE; INFECTION RISK; LUNG FIBROSIS; LUNG FUNCTION; LUNG INFECTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SCHOOL CHILD; STAPHYLOCOCCUS INFECTION; STENOTROPHOMONAS MALTOPHILIA; STENOTROPHOMONAS MALTOPHILIA INFECTION;

EPIDEMIOLOGY; LATENT CLASS MODELS; RISK FACTORS; STENOTROPHOMONAS MALTOPHILIA;

ADOLESCENT; ADULT; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STENOTROPHOMONAS MALTOPHILIA; YOUNG ADULT;

EID: 84888035110     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.05.009     Document Type: Article

References (23)

1. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168(8):918-951.
2. Steinkamp G., Wiedemann B., Rietschel E., Krahl A., Gielen J., Barmeier H., et al. Prospective evaluation of emerging bacteria in cystic fibrosis. J Cyst Fibros 2005, 4(1):41-48.
3. Ballestero S., Virseda I., Escobar H., Suarez L., Baquero F. Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1995, 14(8):728-729.
4. Waters V., Yau Y., Prasad S., Lu A., Atenafu E., Crandall I., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011, 183(5):635-640.
5. 1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008, 178(8):814-821.
6. Marchac V., Equi A., Le Bihan-Benjamin C., Hodson M., Bush A. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J 2004, 23(1):98-102.
7. Li Z., Kosorok M.R., Farrell P.M., Laxova A., West S.E., Green C.G., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293(5):581-588.
8. Levy H., Kalish L.A., Cannon C.L., Garcia K.C., Gerard C., Goldmann D., et al. Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients. Pediatr Pulmonol 2008, 43(5):463-471.
9. Goss C.H., Otto K., Aitken M.L., Rubenfeld G.D. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002, 166(3):356-361.
10. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., Khan U., Kulich M., Kronmal R., et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011, 165(9):847-856.
11. Denton M., Todd N.J., Littlewood J.M. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996, 15(5):402-405.
12. Graff G.R., Burns J.L. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002, 121(6):1754-1760.
13. Talmaciu I., Varlotta L., Mortensen J., Schidlow D.V. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000, 30(1):10-15.
14. Waters V., Atenafu E.G., Salazar J.G., Lu A., Yau Y., Matukas L., et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros 2012, 11(1):8-13.
15. Denton M., Kerr K.G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998, 11(1):57-80.
16. Saiman L., Chen Y., Gabriel P.S., Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002, 46(4):1105-1107.
17. Stanojevic S., Wade A., Cole T.J., Lum S., Custovic A., Silverman M., et al. Spirometry centile charts for young Caucasian children: the Asthma UK Collaborative Initiative. Am J Respir Crit Care Med 2009, 180(6):547-552.
18. Cystic Fibrosis Canada Canadian Patient Data Registry Report 2010, Toronto, Canada.
19. Waters V., Atenafu E.G., Lu A., Yau Y., Tullis E., Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros Jan 4 2013, [Epub ahead of print].
20. Rabe-Hesketh S., Skrondal A. Classical latent variable models for medical research. Stat Methods Med Res 2008, 17(1):5-32.
21. Johnson C., Butler S.M., Konstan M.W., Morgan W., Wohl M.E. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003, 123(1):20-27.
22. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2(1):29-34.
23. Herr M., Just J., Nikasinovic L., Foucault C., Le Marec A.M., Giordanella J.P., et al. Risk factors and characteristics of respiratory and allergic phenotypes in early childhood. J Allergy Clin Immunol 2012, 130(2):389-396. [e4].